eFFECTOR Therapeutics Obtains $40,000,000 Series B Financing

  • Feed Type
  • Date
    12/22/2015
  • Company Name
    eFFECTOR Therapeutics
  • Mailing Address
    11180 Roselle Street San Diego, CA 92121 USA
  • Company Description
    eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention.
  • Website
    http://www.effector.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The funds will support an open-label Phase 1/2 trial that will evaluate daily oral administration of eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, in patients with advanced solid tumors. The Series B proceeds will fund multiple expansion arms for eFT508 in solid tumors and lymphoma, as well as advancing the company’s second program into the clinic.
  • M&A Terms
  • Venture Investor
    Altitude Life Science Ventures
  • Venture Investor
    AbbVie Biotech Ventures
  • Venture Investor
    BioMed Ventures